Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-09

Clinical Trial Update: Intravitreal Aflibercept Injection in Vision Impairment Due to DME [Phase 3]

View source ↗

Summary

Phase 3 trial update for intravitreal aflibercept in vision impairment due to diabetic macular edema (DME) has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EYLEA (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Diabetes Mellitus, Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2014-09-09